A group of 639 bone lesions was reviewed in order to study the features of the aneurysmal bone cyst and its association with other conditions. A diagnosis of primary aneurysmal bone cyst not associated with any other bone lesion was made in 87 patients. In 36 additional patients the gross and microscopic changes of aneurysmal bone cyst were identified as part of some other solid bone lesion. Fourteen of these additional cases were associated with giant cell tumor (96 cases studied), six with chondroblastoma (41 cases studied), three with chondromyxoid fibroma (45 cases studied), two with nonossifying fibroma (68 cases studied), four with osteoblastoma (61 cases studied), one with fibrosarcoma (50 cases studied), three with fibrous histiocytoma (45 cases studied), two with osteosarcoma (100 cases studied), and one with fibrous dysplasia (42 cases studied). The age, site, and sex distribution of the cases associated with another lesion compares closely with that of the solid lesion concerned, supporting the concept that the aneurysmal bone cyst component is secondary.
THE JOURNAL OF BONE AND JOINT SURGERY THE DIAGNOSIS AND TREATMENT OF PIGMENTED VILLONODULAR SYNOVITIS 291 self-perpetuating process which led ultimately to pigmented villonodular synovitis. Geschickter and Copeland (1949) suggested that the lesions originate from osteoclasts in sesamoid bones, but the anatomical sites of the lesions (fingers, hips, knees, ankles) make this view untenable.
Summary.-The paper presents a detailed comparison of the anatomical distribution and frequency of clinically evident metastases in 152 cases of osteosarcoma, and autopsy findings in 43 cases. The behaviour of long bone tumours is contrasted with those arising elsewhere, which tend to metastasize less widely because of early death from effects of the primary tumour. In both clinical and autopsy series long bone tumours produced lung metastases (LM) in over 90% of patients dying with metastases, but the terminal frequency of extra-pulmonary metastases (EPM) rises from a clinical level of 33% to 83% at autopsy.There was little difference between tumours of the major long bones in the frequency of either LM or EPM, but EPM from the humerus tended to be fewer and sited above the diaphragm and from the femur below it. EPM most often involved other bones, notably vertebrae and pelvis. Not more than 10% of tumours invaded regional lymph nodes but terminally a quarter of the long bone tumours had metastasized to heart and abdomen. The infrequency of metastases in muscle was confirmed.The median time for LM was 5-6 months after starting treatment, for EPM 9-10. months. First metastases after 24 months were infrequent, especially in children. With delay in the appearance of metastases, whether LM or EPM, post-metastatic survival lengthened. Neither age, sex nor mode of treatment of the primary notably affected metastatic frequency, although recurrences were much more numerous when radiotherapy, even with high dosage, was the definitive treatment. Local recurrence usually appeared within 6-8 months and was shown to lead to increased frequency of osseous metastases. It is suggested that terminal dissemination may often be tertiary but not always from a pulmonary secondary. THE PAST 30 years' experience of the treatment of osteosarcoma shows universally bad results for any large series of cases. This is due both to the intrinsic limitations of current therapeutic methods and to concentration upon control or destruction of the primary tumour only, although it becomes increasingly obvious that the overwhelming lethal factor is distant metastatic growth, particularly in the lungs. With tumours of long bones, which comprise the great majority of osteosarcomata presenting in young people, lung secondaries are almost invariably the cause of death, even though metastases in other sites are not infrequent and are also potentially lethal.The explosion in diversity and scope of chemotherapy in the last decade is already producing better prognoses for some solid tumours. It is hoped that the use of cytotoxic drugs in the treatment of osteosarcoma may prolong the disease-free survival in this tumour also. Planned treatment along these lines requires a precise knowledge of tumour behaviour, especially of the dominating metastatic activity. We present an analytical study of the metastatic patterns of osteosarcoma arising in otherwise normal bones, as found both clinically
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.